Navigation Links
Funxional successfully completes initial clinical trial of FX125L, an anti-inflammatory drug with a novel mechanism of action
Date:7/8/2009

CAMBRIDGE (UK). 8th July 2009 / b3c newswire / - Funxional Therapeutics Ltd (Funxional) has announced today the successful completion of the first Phase I study with FX125L, an orally available small molecule which belongs to a new therapeutic class named Broad Spectrum Chemokine Inhibitors (BSCIs).

The Phase I, single ascending dose study was conducted in the United States. FX125L was well tolerated at all doses studied and no serious adverse events or subject withdrawals were observed. The pharmacokinetics of FX125L was linear over the wide dose range studied and consistent with once-daily oral dosing for patients.

We are extremely pleased with the outcome of this initial clinical study with FX125L said Konstantinos Efthymiopoulos, CEO of Funxional Therapeutics. The results in humans are consistent with the preclinical data, suggesting that FX125L has a very wide safety margin, and confirmed the excellent drug-like profile of FX125L.


About Funxional Therapeutics Ltd.
Funxional Therapeutics is a privately held, clinical stage pharmaceutical company based in Cambridge (UK) which focuses on novel anti-inflammatory therapies. FXT is managed by a very experienced team and is financed by Index Ventures and Novo A/S, while its shareholders also include Ipsen and Cambridge University. FXT has research and office facilities in Cambridge.
For more information about FXT, please visit our web site (www.funxionaltherapeutics.com) or contact us by e-mail ( info@funxionaltherapeutics.com ).

About BSCIs

BSCIs are anti-inflammatory compounds with an entirely novel mechanism of action that involves the selective interaction with a well-characterized receptor, resulting in a potent inhibition of inflammatory cell migration. The compounds are anticipated to have broad applicability in inflammatory diseases.
BSCIs are one of the three proprietary technology platforms in FXTs portfolio all of which originated in the University of Cambridge. BSCIs were discovered based upon a strategy that exploits functional screening to develop novel new classes of drugs. FX125L is the lead drug candidate in this novel class, while other BSCIs have been identified as back up molecules or as candidates for development as topical anti-inflammatory agents.

Contact

Konstantinos Efthymiopoulos

CEO of Funxional Therapeutics

+44 1223 451095


'/>"/>
b3c newswire

Related biology news :

1. In troubled economic times, BioSquare 2009 successfully serves as business and innovation starter
2. Salk researchers successfully reprogram keratinocytes attached to a single hair
3. Model successfully predicts large river system fish diversity
4. Scientists successfully treat new mouse model of inflammatory bowel disease
5. Researchers successfully simulate photosynthesis and design a better leaf
6. MIT Holding, Georgia Southern University, and MEVLABS successfully test the PROVECTOR
7. A new milestone in the GMES Space Component Program successfully achieved
8. Life on Mars pregnancy test successfully launched
9. DOE Joint Genome Institute completes soybean genome
10. L-1 Identity Solutions Completes Acquisition of the ID Systems Business from Digimarc Corporation
11. bioMETRX, Inc. Completes Exclusive Licensing Agreement With EZ Print, LLC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/4/2017)... 2017  CES 2017 – Valencell , the ... announced the launch of two new versions of ... biometric sensor modules that incorporate the best of ... expertise. The two new designs include Benchmark BE2.0, ... and Benchmark BW2.0, a 2-LED version of its ...
(Date:12/22/2016)... -- As part of its longstanding mission to improve genetic literacy ... released its latest children,s book, titled The One ... topics of inheritance and variation of traits that are part ... school classrooms in the US. The book ... Killoran , whose previous book with 23andMe, You ...
(Date:12/20/2016)... The rising popularity of mobility services ... stoking significant interest in keyless access systems. Following ... energy (BLE), biometrics and near-field communication (NFC) are ... wireless technologies in the automotive industry. This evolution ... systems opens the market to specialist companies such ...
Breaking Biology News(10 mins):
(Date:1/17/2017)... ... January 17, 2017 , ... ... Factor (RF) to its VALIDATE® SP2 calibration verification / linearity test kit. VALIDATE® ... serum base. Each VALIDATE® SP2 kit is prepared using the CLSI recommended “equal ...
(Date:1/17/2017)... N.J. , Jan. 17, 2017 Roka Bioscience, Inc. ... providing advanced testing solutions for the detection of foodborne pathogens today ... CEO.  Ms. Duseau succeeds Paul Thomas , the Company,s President ... of the Company,s Board of Directors.  The changes are effective today. ... of Directors, effective today. ...
(Date:1/17/2017)... 17, 2017 Research and Markets has ... Diagnostics - Technologies, Markets and Companies" to their offering. ... ... remarkably during the past few years. More than 1,000 companies ... and 342 of these are profiled in the report along ...
(Date:1/17/2017)... ... 17, 2017 , ... Pono Ola , a mind-body wellness firm on ... the official launch of its much-anticipated Pono Board: a re-invented fitness and anti-fatigue balance ... for over a year, the patented Pono Board is the world’s only exercise balance ...
Breaking Biology Technology: